Concepedia

U. Ohnmacht

UO

12

Publications

665

Citations

11

H-Index

1997

Active since

Affiliations

Eli Lilly (Germany)(Current)

Eli Lilly (United States)

Universitat Autònoma de Barcelona

Freie Universität Berlin

Spanish National Cancer Research Centre

U. Ohnmacht is an author at Eli Lilly (Germany) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1997–2018

12

Publications

12

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Christophe Massard, A. Ázaro, Jean‐Charles Soria et al. · Annals of Oncology · 2018 · 159 citations · Full text

Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer

K. Possinger, M. Kaufmann, Robert Coleman et al. · Anti-Cancer Drugs · 1999 · 131 citations

Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma

Jürgen R. Fischer, U. Ohnmacht, Norman Rieger et al. · Lung Cancer · 2006 · 94 citations

, , +9

Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine

Jürgen R. Fischer, U. Ohnmacht, Norman Rieger et al. · Lung Cancer · 2006 · 73 citations

, , +7

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations

, , +6

Rows per page

1–5 of 12